sofosbuvir

Details:

Sofibuvir is a prodrug that metabolizes into the active antiviral 2' -deoxy-2 '-alpha-fluoro-β-c-methyluridine 5' -monophosphate and is currently in phase 3 clinical trials for the treatment of hepatitis C. Studies have shown that Sofibuvir is a nucleotide inhibitor of hepatitis C virus and has a selective inhibitory effect on HCVNS5B polymerase. Sofibuvir, also known as Sofibuvir or Sofloubuvir, is the world's first oral treatment for hepatitis C. It is one of the most important new drugs approved in the United States in 2013. When used for the treatment of specific genotypes of chronic hepatitis C, it can eliminate the need for the traditional injectable drug interferon (IFN). Developed by Gilead Sciences, the world's largest maker of anti-HIV drugs, the drug is known as Sofosbuvir and Sovaldi, with peak global sales likely to exceed $10 billion. On December 6, 2013, the US Food and Drug Administration (FDA) approved Sofibuvir (Sovaldi) for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi is the first safe, effective drug to treat certain types of HCV infection without the use of interferon. Hepatitis C is a viral disease that can cause inflammation of the liver, leading to weakened liver function or liver failure. Most patients with HCV infection do not develop Chemicalbook symptoms until liver damage becomes more apparent, a process that can take several years. Some chronic HCV infections develop scarring and cirrhosis over many years, which can lead to complications such as bleeding, jaundice (yellowing of the eyes or skin), ascites, infection, or liver cancer. About 3.2 million Americans are infected with hepatitis C virus, according to the Centers for Disease Control and Prevention. Sofibvir is a nucleotide analogue inhibitor that blocks a specific protein that hepatitis C virus needs to replicate. Sofibuvir is used as an antiviral combination therapy for chronic HCV infection. There are several different types of HCV infection. Depending on the type of HCV infection a patient has, treatment options may include sofibuvir and ribavirin, or sofibuvir, ribavirin and peginterferon alpha. Ribavirin and pegylated interferon alpha are also two drugs used to treat HCV infection. Sofibuvir is the third drug to be approved under FDA breakthrough therapy status. If preliminary clinical evidence shows that a drug provides a substantial improvement over existing treatments for patients with serious or life-threatening diseases, sponsors can apply for breakthrough therapy status with the FDA. Us patents valid: March 26, 2029 (US patents 7964580 and 8334270), April 3,2025 (US patents 7429572 and 8415322).